Breast Cancer Research and Treatment

, Volume 172, Issue 2, pp 437–444 | Cite as

Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer

  • Soo Youn Bae
  • Seok Jin Nam
  • Yongsik Jung
  • Sae Byul Lee
  • Byung-Woo Park
  • Woosung Lim
  • Sung Hoo Jung
  • Hsien Wen Yang
  • Seung Pil Jung
Clinical trial



TP53 mutation is the most common mutation in breast cancer, and it is considered a target marker of triple-negative breast cancer (TNBC). We investigated whether expression of p53 detected by immunochemical staining predicts the chemotherapy response of TNBC.


A total of 11,393 TNBC patients who had between stage I and stage III enrolled in the Korean Breast Cancer Society Registry database from January 1, 2000 to December 31, 2015. There were 6,331 ‘p53-positive (+) TNBC’ patients and 5062 ‘p53-negative (−) TNBC’ patients.


In univariate analysis, p53(+) TNBC had a worse prognosis than p53(−) TNBC in patients not receiving chemotherapy (P = 0.003). However, there was no difference in prognosis between p53(+) TNBC and p53(−) TNBC for patients receiving chemotherapy. In multivariate analysis adjusted for age and stage, the risk of p53(+) TNBC was 1.84 times higher than that of p53(−) TNBC in the non-chemotherapy group. However, there was no difference between p53(+) TNBC and p53(−) TNBC in patients receiving chemotherapy. In p53(+) TNBC, the risk was 0.6-fold lower when chemotherapy was administered than when chemotherapy was not administered. However, in p53(−) TNBC, there was no risk reduction effect by chemotherapy.


The prognosis of p53(+) TNBC has worse than p53(−) TNBC, but the risk for survival was significantly reduced with chemotherapy. It suggests that p53(+) TNBC would be more sensitive to chemotherapy than p53(−) TNBC.


Triple-negative breast cancer Chemotherapy Prognosis P53 Immunohistochemistry 



This article was supported by the Korean Breast Cancer Society. This work was supported by the National Research Foundation of Korea (2017R1D1A1B03028103).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

For this type of study informed consent is not required.


  1. 1.
    Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO (2007) Prognostic markers in triple-negative breast cancer. Cancer 109(1):25–32CrossRefGoogle Scholar
  2. 2.
    Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24(36):5652–5657CrossRefGoogle Scholar
  3. 3.
    Brenton JD, Carey LA, Ahmed AA, Caldas C (2005) Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 23(29):7350–7360CrossRefGoogle Scholar
  4. 4.
    Network CGA (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61–70CrossRefGoogle Scholar
  5. 5.
    Ahn SH, Yoo KY (2006) Chronological changes of clinical characteristics in 31,115 new breast cancer patients among Koreans during 1996–2004. Breast Cancer Res Treat 99(2):209–214CrossRefGoogle Scholar
  6. 6.
    Ahn SH, Son BH, Kim SW, Kim SI, Jeong J, Ko SS, Han W (2007) Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea—a report from the Korean Breast Cancer Society. J Clin Oncol 25(17):2360–2368CrossRefGoogle Scholar
  7. 7.
    Synnott NC, Bauer MR, Madden S, Murray A, Klinger R, O’Donovan N, O’Connor D, Gallagher WM, Crown J, Fersht AR et al (2018) Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigation with the anti-p53 drug, PK11007. Cancer Lett 414:99–106CrossRefGoogle Scholar
  8. 8.
    Duffy MJ, Synnott NC, Crown J (2018) Mutant p53 in breast cancer: potential as a therapeutic target and biomarker. Breast Cancer Res Treat 170(2):213–219CrossRefGoogle Scholar
  9. 9.
    Blagosklonny MV (1997) Loss of function and p53 protein stabilization. Oncogene 15(16):1889–1893CrossRefGoogle Scholar
  10. 10.
    Thor AD, Moore DH, Edgerton II, Kawasaki SM, Reihsaus ES, Lynch E, Marcus HT, Schwartz JN, Chen L, Mayall LC (1992) BH et al: Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 84(11):845–855CrossRefGoogle Scholar
  11. 11.
    Brosh R, Rotter V (2009) When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 9(10):701–713CrossRefGoogle Scholar
  12. 12.
    Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M (2007) TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26(15):2157–2165CrossRefGoogle Scholar
  13. 13.
    Joerger AC, Fersht AR (2016) The p53 pathway: origins, inactivation in cancer, and emerging therapeutic approaches. Annu Rev Biochem 85(1):375–404CrossRefGoogle Scholar
  14. 14.
    Abdel-Fattah R, Challen C, Griffiths TR, Robinson MC, Neal DE, Lunec J (1998) Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis. Br J Cancer 77(12):2230–2238CrossRefGoogle Scholar
  15. 15.
    George B, Datar RH, Wu L, Cai J, Patten N, Beil SJ, Groshen S, Stein J, Skinner D, Jones PA et al (2007) p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. J Clin Oncol 25(34):5352–5358CrossRefGoogle Scholar
  16. 16.
    Lipponen P, Ji H, Aaltomaa S, Syrjanen S, Syrjanen K (1993) p53 protein expression in breast cancer as related to histopathological characteristics and prognosis. Int J Cancer 55(1):51–56CrossRefGoogle Scholar
  17. 17.
    Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bieche I et al (2006) The clinical value of somatic TP53 gene mutations in 1794 patients with breast cancer. Clin Cancer Res 12(4):1157–1167CrossRefGoogle Scholar
  18. 18.
    Coates AS, Millar EK, O’Toole SA, Molloy TJ, Viale G, Goldhirsch A, Regan MM, Gelber RD, Sun Z, Castiglione-Gertsch M et al (2012) Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX. Breast Cancer Res 14(6):R143CrossRefGoogle Scholar
  19. 19.
    Lara JF, Thor AD, Dressler LG, Broadwater G, Bleiweiss IJ, Edgerton S, Cowan D, Goldstein LJ, Martino S, Ingle JN et al (2011) p53 Expression in node-positive breast cancer patients: results from the cancer and leukemia group B 9344 Trial (159905). Clin Cancer Res 17(15):5170–5178CrossRefGoogle Scholar
  20. 20.
    Fernandez-Cuesta L, Oakman C, Falagan-Lotsch P, Smoth KS, Quinaux E, Buyse M, Dolci MS, Azambuja ED, Hainaut P, Dell’orto P et al (2012) Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. Breast Cancer Res 14(3):R70CrossRefGoogle Scholar
  21. 21.
    Silwal-Pandit L, Vollan HK, Chin SF, Rueda OM, McKinney S, Osako T, Quigley DA, Kristensen VN, Aparicio S, Borresen-Dale AL et al (2014) TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance. Clin Cancer Res 20(13):3569–3580CrossRefGoogle Scholar
  22. 22.
    Bertheau P, Turpin E, Rickman DS, Espie M, de Reynies A, Feugeas JP, Plassa LF, Soliman H, Varna M, de Roquancourt A et al (2007) Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med 4(3):e90CrossRefGoogle Scholar
  23. 23.
    Bertheau P, Plassa F, Espie M, Turpin E, de Roquancourt A, Marty M, Lerebours F, Beuzard Y, Janin A, de The H (2002) Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet 360(9336):852–854CrossRefGoogle Scholar
  24. 24.
    Lehmann-Che J, Andre F, Desmedt C, Mazouni C, Giacchetti S, Turpin E, Espie M, Plassa LF, Marty M, Bertheau P et al (2010) Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers. The Oncologist 15(3):246–252CrossRefGoogle Scholar
  25. 25.
    Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong C-O, Calogrias D, Buraimoh A et al (2010) Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 28(7):1145–1153CrossRefGoogle Scholar
  26. 26.
    Varna M, Lehmann-Che J, Turpin E, Marangoni E, El-Bouchtaoui M, Jeanne M, Grigoriu C, Ratajczak P, Leboeuf C, Plassa LF et al (2009) p53 dependent cell-cycle arrest triggered by chemotherapy in xenografted breast tumors. Int J Cancer 124(4):991–997CrossRefGoogle Scholar
  27. 27.
    Jackson JG, Pant V, Li Q, Chang LL, Quintas-Cardama A, Garza D, Tavana O, Yang P, Manshouri T, Li Y et al (2012) p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell 21(6):793–806CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Breast and Endocrine Surgery, Department of Surgery, Korea University Anam HospitalKorea University College of MedicineSeoulRepublic of Korea
  2. 2.Department of Surgery, Samsung Medical CenterSungkyunkwan University School of MedicineSeoulRepublic of Korea
  3. 3.Department of SurgeryAjou University School of MedicineGyeonggi-doRepublic of Korea
  4. 4.Department of Surgery, Asan Medical CenterUniversity of Ulsan College of MedicineSeoulRepublic of Korea
  5. 5.Department of SurgeryYonsei University College of MedicineSeoulRepublic of Korea
  6. 6.Department of Surgery, Ewha Womans University Mokdong HospitalEwha Womans University College of MedicineSeoulRepublic of Korea
  7. 7.Department of Surgery, Chonbuk National University HospitalChonbuk National University Medical SchoolJeonjuRepublic of Korea

Personalised recommendations